OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2025.15330 OL-30-6-15330 Articles Prognostic value of the postoperative CALLY index in T1/T2 clear cell renal cell carcinoma HirataHiroshi FujiiNakanori TokunagaTakanori ShimizuKosuke KobayashiKeita ShiraishiKoji Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan Correspondence to: Dr Hiroshi Hirata, Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan, E-mail: hiro1333@yamaguchi-u.ac.jp 122025 10102025 30 6 584 08072025 08082025 Copyright © 2025, Spandidos Publications 2025

Identifying patients with renal cell carcinoma (RCC) at risk of postoperative recurrence remains challenging, particularly in those with early-stage disease. The objective of the present study was to evaluate the prognostic utility of the C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index and other haematological biomarkers in patients with pathologic T1/T2 clear-cell RCC (ccRCC). In total, data from 253 patients with pT1/T2 ccRCC who underwent nephrectomies were retrospectively analysed. Preoperative and postoperative levels of CRP, neutrophil-to-lymphocyte ratio (NLR) and CALLY index were assessed, and cut-off values were determined using receiver operating characteristic curves. Prognostic significance was evaluated using Kaplan-Meier and Cox regression analyses. A postoperative CALLY index of ≤2.163 was significantly associated with shorter progression-free survival [hazard ratio (HR)=3.64] and overall survival (HR=4.98). A preoperative NLR of ≥3.015 also predicted recurrence (HR=2.74). Furthermore, the postoperative CALLY index demonstrated the highest predictive accuracy for overall survival (area under the curve=0.8141). In conclusion, the postoperative CALLY index is a robust and accessible biomarker for recurrence and survival in patients with T1/T2 ccRCC, and may guide postoperative surveillance strategies.

 C-reactive protein-albumin-lymphocyte index progression-free survival T1/T2 clear cell renal cell carcinoma Funding: No funding was received. Introduction

Renal cell carcinoma (RCC) accounts for approximately 2–3% of adult malignancies (1) and remains a notable cause of cancer-related mortality worldwide. Clear-cell RCC (ccRCC) has been identified as the predominant histological subtype, accounting for approximately 75% of all RCC cases and the majority of RCC-specific deaths (2,3).

Surgical resection remains the mainstay treatment for localised RCC. Although patients with pT1 and pT2 tumours typically exhibit favourable outcomes, a subset experiences ‘late recurrence’ several years postoperatively, complicating follow-up strategies (4). Several inflammatory and nutritional blood biomarkers, including C-reactive protein (CRP) and the neutrophil-to-lymphocyte ratio (NLR), have been explored to improve risk stratification; however, none have gained widespread clinical adoption (5,6). These markers were selected based on their established relevance in reflecting systemic inflammation (CRP and NLR) and nutritional status (albumin and lymphocytes). As inflammation and immune suppression are known contributors to the progression of RCC, their integration into a composite index, such as the CRP-albumin-lymphocyte (CALLY) index, offers a biologically meaningful and clinically accessible prognostic tool.

The CALLY index has recently emerged as a novel composite biomarker that reflects systemic inflammation, nutritional status, and immune competence. Specifically, it has been highlighted that these markers capture distinct but interrelated aspects of cancer biology, inflammation (CRP, NLR), nutritional status (albumin), and immune competence (lymphocyte count), and that their composite use via the CALLY index may provide a more comprehensive risk assessment in RCC (5–12). We have previously demonstrated the prognostic value of the CALLY index in patients with advanced RCC (pT3) (7). Nevertheless, whether the CALLY index retains its clinical utility in lower-stage disease remains unknown.

In the current study, we aimed to evaluate the predictive relevance of the CALLY index for postoperative recurrence and survival in patients with pT1/pT2 ccRCC, with an emphasis on comparing preoperative and postoperative biomarker values.

 Materials and methods <sec> <title>Study population

This retrospective study included 253 patients with pathologically confirmed ccRCC, staged as pT1 or pT2, who underwent partial or radical nephrectomy at Yamaguchi University Hospital between October 2005 and September 2023. Patient demographics, clinical characteristics, and pathological features were extracted from the institutional records. The median patient age was 67 years (range, 28–92 years; 172 male, 81 female). The median follow-up period was 37.9 months (range, 1–194 months). This study was approved by the Institutional Review Board of the Graduate School of Medicine, Yamaguchi University (IRB #2023-042), and all patients provided written informed consent.

 Data collection and biomarker assessment

Data regarding clinical and laboratory parameters, including age, sex, body mass index, tumour stage, Fuhrman grade, and presence of sarcomatoid differentiation, were collected. Laboratory values included serum albumin (g/dl), CRP (mg/dl), absolute neutrophil count, and absolute lymphocyte count (cells/µl). The CALLY index is calculated as follows: CALLY index=(Albumin × Lymphocyte count)/CRP.

Peripheral blood samples were obtained at two time points: Within two weeks prior to surgery (preoperative) and approximately one month after surgery (postoperative). To minimise the influence of perioperative physiological changes, only samples collected at least one month postoperatively were used for postoperative analysis.

 Statistical analysis

Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive ability of CRP, NLR, and CALLY index for progression-free survival (PFS) and overall survival (OS). The optimal cut-off values were determined using the Youden index. The sensitivity, specificity, positive predictive value, and negative predictive value were also calculated.

Kaplan-Meier survival analysis was used to estimate PFS and OS, and survival distributions were compared using the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify independent predictors. Hazard ratios (HRs) with 95% confidence intervals (CIs) are reported. P<0.05 was considered to indicate a statistically significant difference. Regarding association with clinical parameters, Wilcoxon rank-sum test was used. All statistical analyses were performed using the JMP Pro software (version 16.0; SAS Institute Inc., Cary, NC, USA).

 Results <sec> <title>Patient characteristics

The patient characteristics are summarized in Table I. The median age was 67 years, with 67.98% males and 32.02% females. Among the 253 patients included in the study, 239 (94.5%) were classified as pT1, and 14 (5.5%) as pT2. Postoperative recurrence occurred in 21 (8.3%) patients. At the time of the last follow-up, 236 (90.9%) patients had survived (Table I).

 ROC curve analysis

Figs. 1 and 2 showed that ROC analysis was used to evaluate the predictive ability of CRP, NLR, and CALLY index for PFS and OS. For PFS prediction using postoperative data, the CALLY index showed the highest specificity (82.8%), with an area under the curve (AUC) of 0.6525 and a cut-off value of 2.163. In contrast, preoperative CRP (cut-off: 0.2950) and NLR (cut-off: 3.015) had lower discriminative power (AUCs=0.6965 and 0.6089, respectively).

Likewise, the postoperative CALLY index exhibited the highest performance for OS prediction, with an AUC of 0.8141, sensitivity of 76.5%, and specificity of 79.2% (cut-off: 3.399). Postoperative CRP level and NLR also exhibited notable performances, with AUCs of 0.8062 and 0.7682, respectively.

 Kaplan-Meier survival analysis

Kaplan-Meier survival curves revealed that patients with a postoperative CALLY index ≤2.163 had significantly shorter PFS and OS than those with higher values (log-rank P=0.0026 and P=0.002, respectively) (Figs. 3 and 4). Similarly, high preoperative NLR (≥3.015) and high postoperative CRP (≥0.3850) were associated with significantly shorter PFS and OS.

 Cox proportional hazards regression

Univariate analysis identified preoperative NLR ≥3.015 (HR=2.74; 95% CI: 1.16–6.47; P=0.0208) and postoperative CALLY index ≤2.163 (HR=3.64; 95% CI: 1.45–8.25; P=0.005) as significant predictors of recurrence (Table II). For OS, postoperative Fuhrman grade ≥3 (HR=6.07; 95% CI: 1.28–28.79; P=0.023) and postoperative CALLY index ≤2.163 (HR=4.98; 95% CI: 1.59–15.56; P=0.0057) were identified as significant predictors associated with recurrence (Table IIIA).

In multivariate analysis, a low postoperative CALLY index (≤2.163) and high Fuhrman grade remained independent predictors of poor OS. In contrast, the CALLY index showed the strongest association with both recurrence and survival outcomes.

 Association with clinical parameters

Subgroup analysis revealed that the CALLY index was significantly lower in patients with pT2 tumours and higher Fuhrman grades (P<0.05) (Table IVA). Although similar trends were observed postoperatively, they did not reach statistical significance (Table IVB).

 Discussion

In this study, we evaluated the prognostic relevance of the CALLY index in patients with pathological T1/T2 ccRCC, focusing on its ability to predict postoperative recurrence and OS.

Our findings demonstrate that the postoperative CALLY index is a superior prognostic marker compared with individual haematologic biomarkers, such as CRP and NLR. Notably, a low postoperative CALLY index (≤2.163) was independently associated with disease recurrence and poor OS, underscoring its clinical relevance in postoperative risk stratification.

Previous studies primarily examined the prognostic value of the CALLY index in advanced RCC (7) and other malignancies (8–10). Our previous study highlighted the significance of this index in patients with pT3 RCC (7). By extending this study to a lower-risk cohort, we demonstrated that the CALLY index remained a robust indicator of prognosis, suggesting broader applicability across disease stages. Importantly, the enhanced prognostic accuracy of postoperative values, compared with preoperative measures, indicates that the resolution of perioperative inflammation may be necessary to reveal the true baseline immune and nutritional status.

The components of the CALLY index, serum albumin level, CRP level, and lymphocyte count have been individually recognised for their prognostic relevance. Hypoalbuminaemia reflects poor nutritional status and systemic inflammation (11,12), CRP is a marker of the acute-phase response and tumour-related inflammation, and lymphopenia indicates impaired immune surveillance (13–15). The integration of these variables into a composite index allows for a more holistic assessment of host-tumour interactions. Our data reinforce the utility of the CALLY index as a composite measure, particularly when assessed in a stable postoperative setting.

The postoperative CALLY index demonstrated stronger predictive power for OS (AUC=0.8141) than either CRP or NLR alone. This supports previous findings observed in patients with gastrointestinal and hepatocellular cancers, in which postoperative inflammatory indices provided improved prognostic resolution (8–10). In RCC, systemic inflammation is associated with disease progression and resistance to therapies such as immune checkpoint inhibitors (ICIs) (16–18). A persistently low postoperative CALLY index may signal sustained inflammation or immune dysfunction, making patients less likely to benefit from ICI monotherapy (19).

Our findings have several important clinical implications. First, the postoperative CALLY index may serve as a cost-effective and non-invasive tool to guide surveillance intensity. Second, patients with low postoperative CALLY index values may benefit from closer follow-up or earlier introduction of adjuvant therapy. Third, this index may aid in the selection of patients for combined ICI and tyrosine kinase inhibitor regimens in future prospective trials.

Nevertheless, the limitations of this study need to be addressed. The retrospective design and single-institution cohort may have introduced selection bias. Additionally, the limited number of recurrence events restricts the statistical power, particularly in multivariate models. Although the Fuhrman grade and tumour stage were included in the analysis, other molecular or genomic features were not assessed. Future studies should incorporate molecular profiling to enhance prognostic modelling and validate our findings in independent cohorts. Furthermore, the retrospective design, single-centre setting, and lack of external validation may limit the generalisability of our findings. In addition, the absence of dynamic postoperative biomarker trends or radiological confirmation of the timing of recurrence warrants cautious interpretation. Future prospective studies incorporating multicentre data and longer follow-up periods are necessary.

To further validate the prognostic role of the CALLY index, future multicentre prospective studies incorporating diverse populations and standardised postoperative sampling protocols are warranted.

Overall, the postoperative CALLY index is a valuable biomarker for identifying patients with T1/T2 ccRCC who have an increased risk of recurrence and mortality. Its incorporation into clinical decision-making may improve individualised follow-up strategies and support the selection of appropriate therapeutic interventions.

In conclusion, the postoperative CALLY index is a reliable and accessible biomarker for predicting recurrence and survival in patients with pathological T1/T2 ccRCC. This index provides superior prognostic accuracy compared with individual haematologic markers and may enhance current risk stratification protocols. Incorporating the CALLY index into postoperative monitoring could improve individualised patient management and inform clinical decision-making regarding adjuvant therapy. The postoperative CALLY index may assist in identifying patients who require close surveillance or early systemic therapy.

 Acknowledgements

Not applicable.

 Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

 Authors' contributions

HH conceived the study and wrote the manuscript. KosS and TT contributed to the data acquisition. NF and KK conducted the statistical analyses. KojS contributed to the analysis of data. HH and TT confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

This study was approved by the Institutional Review Board of the Graduate School of Medicine, Yamaguchi University (IRB #2023-042), and written informed consent was obtained from all participants.

 Patient consent for publication

Written informed consent for publication was obtained from all patients prior to inclusion in the study.

 Competing interests

The authors declare that they have no competing interests.

 References SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin67730201728055103 HaakeSMRathmellWKRenal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?Cancer123200229201710.1002/cncr.3031427861752 RiniBICampbellSCEscudierBRenal cell carcinomaLancet37311191132200910.1016/S0140-6736(09)60229-419269025 CheaibJGPatelHDJohnsonMHGorinMAHautERCannerJKAllafMEPierorazioPMStage-specific conditional survival in renal cell carcinoma after nephrectomyUrol Oncol386.e16.e7202010.1016/j.urolonc.2019.08.01131522864 PichlerMHuttererGCStoeckigtCChromeckiTFStojakovicTGolbeckSEberhardKGergerAMannweilerSPummerKValidation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in RCCBr J Cancer108901907201310.1038/bjc.2013.2823385728 JagdevSPGregoryWVasudevNSHarndenPSimSThompsonDCartledgeJSelbyPJBanksREImproving the accuracy of pre-operative survival prediction in RCC with CRPBr J Cancer10316491656201010.1038/sj.bjc.660597321063409 HirataHFujiiNOkaSNakamuraKShimizuKKobayashiKHiroyoshiTIsoyamaNShiraishiKCALLY index as a novel biomarker for progression in RCCCancer Diagn Progn4748753202410.21873/cdp.1039139502622 IidaHTaniMKomedaKNomiTMatsushimaHTanakaSUenoMNakaiTMaehiraHMoriHSuperiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinomaHPB (Oxford)24101115202210.1016/j.hpb.2021.06.41434244053 FengJWangLYangXChenQClinical significance of preoperative CALLY index in esophageal SCCSci Rep14713202410.1038/s41598-023-51109-w38184747 SakuraiKKuboNHasegawaTNishimuraJIsekiYNishiiTInoueTYashiroMNishiguchiYMaedaKCALLY index in gastric cancer prognosisWorld J Surg4827492759202410.1002/wjs.1235739349360 WuMTHeSYChenSLLiLFHeZQZhuYYHeXChenHClinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinomaBMC Cancer19538201910.1186/s12885-019-5747-531164099 IshizukaMIshizukaMNagataHTakagiKHorieTKubotaKInflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancerAnn Surg24610471051200710.1097/SLA.0b013e318145417118043109 ZhouLCaiXLiuQJianZYLiHWangKJPrognostic role of C-reactive protein in urological cancers: A meta-analysisSci Rep512733201510.1038/srep1273326235332 PatelSHDerweeshIHSaitoKPatilDMeagherMFBindayiAEldefrawyAPatelDNNasseriRYasudaYPreoperative elevation of C-reactive protein is a predictor for adverse oncologic survival outcomes for renal cell carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC)Clin Genitourin Cancer19e206e215202110.1016/j.clgc.2021.02.00333773937 McMillanDCThe systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treat Rev39534540201310.1016/j.ctrv.2012.08.00322995477 LiWWangJThe current state of inflammation-related research in prostate cancer: a bibliometric analysis and systematic reviewFront Oncol141432857202410.3389/fonc.2024.143285739355131 IivanainenSAhvonenJKnuuttilaATiainenSKoivunenJPElevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitorsESMO Open4e000531201910.1136/esmoopen-2019-00053131555483 JohnsonTVAbbasiAOwen-SmithAYoungANKucukOHarrisWBOsunkoyaAOOganKPattarasJPostoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinomaUrology76766e1201010.1016/j.urology.2010.01.052 OnoderaRChibaSNiheiSFujimuraIAkiyamaMUtsumiYNagashimaHKudoKMaemondoMHigh level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: A retrospective studyJ Thorac Dis1542374247202310.21037/jtd-23-8537691668

ROC curve analysis for progression-free survival using pre- and postoperative biomarkers: (A) Preoperative CRP, (B) preoperative NLR, (C) preoperative CALLY index, (D) postoperative CRP, (E) postoperative NLR, (F) postoperative CALLY index. ROC, receiver operating characteristic; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; CALLY, CRP-albumin-lymphocyte.

Figure 1. ROC curve analysis for progression–free survival using pre– and postoperative biomarkers: (A) Preoperative CRP, (B) preoperative NLR, (C) preoperative CALLY index, (D) postoperative CRP, (E)...

ROC curve analysis for OS using pre- and postoperative biomarkers: (A) Preoperative CRP, (B) preoperative NLR, (C) preoperative CALLY index, (D) postoperative CRP, (E) postoperative NLR, (F) postoperative CALLY index. ROC, receiver operating characteristic; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; CALLY, CRP-albumin-lymphocyte; OS, overall survival.

Figure 2. ROC curve analysis for OS using pre– and postoperative biomarkers: (A) Preoperative CRP, (B) preoperative NLR, (C) preoperative CALLY index, (D) postoperative CRP, (E) postoperative NLR, (F)...

Kaplan-Meier survival analysis for PFS stratified by biomarker cut-offs: (A) Preoperative CRP, (B) preoperative NLR, (C) preoperative CALLY index, (D) postoperative CRP, (E) postoperative NLR, (F) postoperative CALLY index. Patients were divided into H and L groups according to the cut-off value determined by receiver operating characteristic curve analysis. CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; CALLY, CRP-albumin-lymphocyte; PFS, progression-free survival; H, high; L, low.

Figure 3. Kaplan–Meier survival analysis for PFS stratified by biomarker cut–offs: (A) Preoperative CRP, (B) preoperative NLR, (C) preoperative CALLY index, (D) postoperative CRP, (E) postoperative NL...

Kaplan-Meier survival analysis for OS stratified by biomarker cut-offs: (A) Preoperative CRP, (B) preoperative NLR, (C) preoperative CALLY index, (D) postoperative CRP, (E) postoperative NLR, (F) postoperative CALLY index. Patients were divided into H and L groups according to the cut-off value determined by receiver operating characteristic curve analysis. CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; CALLY, CRP-albumin-lymphocyte; OS, overall survival; H, high; L, low.

Figure 4. Kaplan–Meier survival analysis for OS stratified by biomarker cut–offs: (A) Preoperative CRP, (B) preoperative NLR, (C) preoperative CALLY index, (D) postoperative CRP, (E) postoperative NLR...

Patient characteristics (T1/T2N0M0, n=253).

Variable Value
Sex, n (%)
  Male 172 (67.98)
  Female 81 (32.02)
Age, years
  Median 67
  Range 28-92
BMI, kg/m2
  Median 23.64
  Range 13.83–37.59
T stage, n (%)
  T1a 191 (75.49)
  T1b 48 (18.97)
  T2a 11 (4.35)
  T2b 3 (1.19)
N stage, n (%)
  N0 253 (100)
  N1 0 (0)
M stage, n (%)
  M0 253 (100)
  M1 0 (0)
Fuhrman grade, n (%)
  G1 94 (37.15)
  G2 140 (55.34)
  G3 16 (6.32)
  G4 3 (1.19)
Sarcomatoid feature, n (%)
    No 250 (98.8)
    Yes 3 (1.2)
Outcome, n (%)
  Progression
  No 232 (91.70)
  Yes 21 (8.3)
Overall survival
  Survival 236 (93.3)
  Death 17 (6.7)

Univariate analysis to predict progression-free survival in pT1/pT2 patients.

Variable Cut-off Comparison HR (95% CI) P-value
Sex - Male vs. Female 1.292572 (0.973913–1.715494) 0.0756
Age, years 67a Older vs. Younger 1.321941 (0.544308–3.21055) 0.5376
BMI, kg/m2 23.64a High vs. Low 1.064536 (0.822657–1.378381) 0.6312
Stage - T2 vs. T1 3.00129 (0.881974–10.21316) 0.0786
Fuhrman grade - 34 vs. 1 + 2 1.473568 (0.194606–11.15796) 0.7074
Preoperative CRP 0.295 High vs. Low 1.919245 (0.807844–4.559671) 0.1398
Preoperative NLR 3.015 High vs. Low 2.748875 (1.166315–6.478798) 0.0208
Preoperative CALLY index 12.46 Low vs. High 1.79135 (0.741854–4.325562) 0.1949
Postoperative CRP 0.2950 High vs. Low 1.919245 (0.807844–4.559671) 0.1398
Postoperative NLR 1.954 High vs. Low 2.690201 (0.985032–7.347159) 0.0535
Postoperative CALLY index 2.163 Low vs. High 3.461179 (1.454691–8.235263) 0.005

Median. CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; CALLY, CRP-albumin-lymphocyte.

Univariate and multivariate analyses to predict overall survival in pT1/pT2 patients.

A, Analyses based on postoperative data
Variable Cut-off Comparison Univariate HR (95% CI) Univariate P-value Multivariate HR (95% CI) Multivariate P-value
Sex - Male vs. Female 1.863947 0.2832 - -
(0.597746–5.812336)
Age, years 67a Older vs. Younger 1.725438 0.2819 - -
(0.638896–4.65981)
BMI, kg/m2 23.64a High vs. Low 2.207195 0.138 - -
(0.775425–6.282635)
Stage - T2 vs. T1 5.324408 0.002 3.225972 0.0463
(1.84181–15.3921) (1.019327–10.20957)
Fuhrman grade - 34 vs. 1+2 6.075185 0.023 3.657307 0.1216
(1.281854–28.79258) (0.708305–18.88436)
CRP 0.385 High vs. Low 6.889604 0.0027 5.828419 0.1371
(1.951844–24.31887) (0.570453–59.54996)
NLR 2.189 High vs. Low 8.108854 0.0057 4.462875 0.0652
(1.840612–35.72372) (0.910259–21.88086)
CALLY index 3.399 Low vs. High 4.981984 0.0057 1.771683 0.5931
(1.594653–15.56462) (0.217442–14.43542)
B, Analyses based on preoperative data
Variable Cut-off Comparison Univariate HR (95% CI) Univariate P-value Multivariate HR (95% CI) Multivariate P-value
Sex - Male vs. Female 1.863947 0.2832 - -
(0.597746–5.812336)
Age, years 67a Older vs. Younger 1.725438 0.2819 - -
(0.638896–4.65981)
BMI, kg/m2 23.64a High vs. Low 2.207195 0.138 - -
(0.775425–6.282635)
Stage - T2 vs. T1 5.324408 0.002 2.46747 0.1357
(1.84181–15.3921) (0.753225–8.083124)
Fuhrman grade - 34 vs. 1+2 6.075185 0.023 3.878816 0.1004
(1.281854–28.79258) (0.769975–19.53987)
CRP 0.155 High vs. Low 4.698866 0.0168 1.033698 0.9773
(1.321837–16.70353) (0.105675–10.11152)
NLR 2.473 High vs. Low 3.957946 0.0099 2.330853 0.1416
(1.392138–11.25272) (0.754118–7.204278)
CALLY index 5.130 Low vs. High 5.675808 0.0031 3.058945 0.3013
(1.799224–17.90483) (0.367179–25.48385)

Median. CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; CALLY, CRP-albumin-lymphocyte.

Association of CALLY index with several clinical factors.

A, Preoperative (n=249)
Parameter Group n CALLY index (mean) P-valuea
Sex Male 169 120.698 0.1707
Female 80 134.088 Reference
Age (median, 67 years) Low 125 121.344 Reference
High 124 128.685 0.4213
BMI (median, 23.64 kg/m2) Low 125 128.688 Reference
High 124 121.282 0.4172
TNM T1 235 129.017 Reference
T2 14 57.571 0.0003
Fuhrman grade G1 + G2 232 127.563 Reference
G3 + G4 z17 90.029 0.0381
B, Postoperative (n=253)
Parameter Group n CALLY index (mean) P-valuea
Sex Male 172 123.267 0.2311
Female 81 134.926 Reference
Age (median, 67 years) Low 127 118.386 0.0601
High 126 135.683 Reference
BMI (median, 23.64 kg/m2) Low 126 134.992 Reference
High 127 119.071 0.0836
TNM T1 239 128.264 Reference
T2 14 105.429 0.2565
Fuhrman grade G1 + G2 235 128.815 Reference
G3 + G4 18 103.306 0.1541

Wilcoxon rank-sum test.